Immune Design
Immune Design Corp. (Form: 4, Received: 10/30/2017 17:05:13)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

COLUMN GROUP L P
2. Issuer Name and Ticker or Trading Symbol

Immune Design Corp. [ IMDZ ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

1700 OWENS STREET, SUITE 500
3. Date of Earliest Transaction (MM/DD/YYYY)

10/27/2017
(Street)

SAN FRANCISCO, CA 94158
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   10/27/2017     P    2681000   (1) A $4.10   6642942   D   (2) (3)  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Reflects the purchase of shares by Ponoi Capital, LP ("Ponoi LP") in the follow-on offering of Common Stock of Immune Design Corp. that closed on October 27, 2017.
(2)  Includes shares directly held by Ponoi LP, The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares.
(3)  (Continued From Footnote 2) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
COLUMN GROUP L P
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X

COLUMN GROUP GP, LP
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X

COLUMN GROUP II, LP
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X

Column Group II GP, LP
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X

PONOI CAPITAL, LP
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X

Ponoi Management, LLC
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X

GOEDDEL DAVID V
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X

Kutzkey Tim
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158

X


Signatures
THE COLUMN GROUP, LP, /s/ Peter Svennilson, Name: Peter Svennilson, Managing Partner 10/30/2017
** Signature of Reporting Person Date

THE COLUMN GROUP GP, LP, /s/ Peter Svennilson, Name: Peter Svennilson, Managing Partner 10/30/2017
** Signature of Reporting Person Date

THE COLUMN GROUP II, LP, /s/ Peter Svennilson, Name: Peter Svennilson, Managing Partner 10/30/2017
** Signature of Reporting Person Date

THE COLUMN GROUP II GP, LP, /s/ Peter Svennilson, Name: Peter Svennilson, Managing Partner 10/30/2017
** Signature of Reporting Person Date

PONOI CAPITAL, LP, /s/ Peter Svennilson, Name: Peter Svennilson, Managing Partner 10/30/2017
** Signature of Reporting Person Date

PONOI MANAGEMENT, LLC, /s/ Peter Svennilson, Name: Peter Svennilson, Managing Partner 10/30/2017
** Signature of Reporting Person Date

/s/ David V. Goeddel, Name: David V. Goeddel 10/30/2017
** Signature of Reporting Person Date

/s/ Tim Kutzkey, Name: Tim Kutzky 10/30/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.